Summary Since 1989, 18 second-generation antiseizure medications have reached the
market, resulting in a greatly increased range of treatment options for patients and …

Background Until the early 1990s six major compounds (carbamazepine, ethosuximide,
phenobarbital, phenytoin, primidone, and valproic acid) were available for the treatment of …

Antiepileptic drugs (AEDs) are relatively cheap but high volumes of prescriptions mean that
substantial drug-budget savings may be possible by switching from innovator brands to …

Treatment decisions in epilepsy need to be individualised on the basis of careful analysis of
the risk-benefit ratio of each available option. Key decision steps include the time at which …

The choice of antiepileptic drugs (AEDs) is rapidly increasing. This review looks at the
evidence that guides the decision of which AED to start as monotherapy and aims to aid the …

Despite the introduction of many second-generation antiepileptic drugs (AEDs) in the past
15 years, a third of patients with epilepsy remain refractory to available treatments, and …

In the past decade, 8 new antiepileptic drugs have been approved for use in the United
States, offering many new treatment options to patients with epilepsy. With expanding use of …

The administration of antiepileptic drugs (AEDs) is the first treatment of epilepsy, one of the
most common neurological diseases. Therapeutic guidelines include newer AEDs as front …

ContextThe past decade has brought many advances to the treatment of epilepsy, including
many new pharmacological agents. Primary care physicians often care for patients with …

Drug-resistant epilepsy occurs in 25–30% of patients. Furthermore, treatment with a first-
generation antiseizure drug (ASD) fails in 30–40% of individuals because of their intolerable …